Skip to main content
SpringerLink
Log in

Was ist gesichert in der medikamentösen Therapie der stabilen Angina pectoris?

  • Chapter
Koronare Herzkrankheit

  • 10 Accesses

Zusammenfassung

In der täglichen ärztlichen Beschäftigung mit der koronaren Herzkrankheit nimmt die medikamentöse Therapie der Angina pectoris den breitesten Raum ein. Diese Therapie dient einem seit jeher wichtigsten Ziel der ärztlichen Arbeit, nämlich der Linderung und Beseitigung von Beschwerden. Von dieser Zielsetzung her handelt es sich also um eine symptomorientierte palliative Therapie, die an der eigentlichen Grunderkrankung, also der stenosierenden Koronarsklerose, keine Heilung verspricht oder erstrebt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abrams J (1985) New nitroglycerin formulations: Transdermal and transmucosal nitroglycerin. Z Kardiol 74: 10–15

    PubMed  Google Scholar 

  2. Akhas F, Jefferies S, Jackson G (1985) Isosorbide-5-mononitrate-effective monotherapy in chronic stable angina. Z Kardiol [Suppl 4] 74: 16–20

    Google Scholar 

  3. Alderman EL, Davies RO, Crowley JJ, et al (1975) Dose response effectiveness or propranolol for the treatment of angina pectoris. Circulation 51: 964–973

    PubMed  CAS  Google Scholar 

  4. Abshagen U (1985) Pharmacokinetics of ISDN, sustained-release ISDN and IS-5-MN. In: Cohn JN, Rittinghausen R (eds) Mononitrates. Springer, Berlin Heidelberg New York Tokyo, pp 53–66

    Google Scholar 

  5. Arnim Th v, Autenrieth G, Bolte HD (1984) Acute myocardial infarction during continous electrocardiographic ST-segment recording: Possible role of bradycardia and hypotension induced by glyceryl trinitrate. Br Heart J 51: 575–577

    Article  Google Scholar 

  6. Badger RS, Brown BG, Gallery GhA, Bolson EL, Dodge HT (1985) Coronary artery dilatation and hemodynamic response after isosorbide dinitrate therapy in patients with coronary artery disease. Am J Cardiol 56: 390–395

    Article  PubMed  CAS  Google Scholar 

  7. Bala Subramanian V, Bowles M, Penalver H, Davies AB, Raftery EB (1981) Verapamil in ischemic heart disease — an objektive study in 100 patients. In: Zanchetti A, Krikler DM (eds) Calcium antagonism in cardiovascular therapy. Excerpta Medica, Amsterdam Oxford Princeton, pp 118–139

    Google Scholar 

  8. Bassenge E (1982) Pharmakologische Bases der Therapie mit Molsidomin. Herz 7: 296–306

    PubMed  CAS  Google Scholar 

  9. Blasini R, Brügmann U, Mannes A, Froer KL, Hall D, Rudolph W (1980) Wirksamkeit von Isosorbiddinitrat in retardierter Form bei Langzeitbehandlung. Herz 5: 298–305

    PubMed  CAS  Google Scholar 

  10. Blasini R, Brügmann U, Mannes A, Rudolph W (1982) Molsidomin zur Langzeitbehandlung der Angina pectoris. Herz 7: 307–316

    PubMed  CAS  Google Scholar 

  11. Danaky DT, Burwell DT, Aronow WS, Praksh R (1977) Sustained hemodynamic and anti- anginal effect of high dose oral isosorbide dinitrate. Circulation 55: 381–387

    Google Scholar 

  12. Droste C (1984) Neurophysiologie des Koronarschmerzes. In: Roskamm H (Hrsg) Koronarerkrankungen. (Handbuch der inneren Medizin, Bd IX/3.) Springer, Berlin Heidelberg New York Tokyo, S 157–174

    Google Scholar 

  13. Eichelbaum M, Sornogyi A (1980) Verapamil distribution in health and the disease State. In: Zanchetti A, Krikler DM (eds) Calcium antagonism in cardiovascular therapy. Excerpta Medica, Amsterdam Oxford Princeton, pp 64–72

    Google Scholar 

  14. Erdmann E (1979) Klinische Pharmakologie. In: Bolte HD (Hrsg) Therapie mit Betarezeptoren-blockern. Springer, Berlin Heidelberg New York, S 1–17

    Chapter  Google Scholar 

  15. Ganz W, Marcus HS (1972) Failure of intracoronary nitroglycerin to alleviate pacing-induced angina. Circulation 46: 880–889

    PubMed  CAS  Google Scholar 

  16. Hopf R, Pietruska M, Dowinski S, Kaltenbach M (1983) Combined administration of various doses of nifedipine and isosorbiddinitrate in patients with angina pectoris. In: Kaltenbach M, Neufeld HN (eds) 5th International Adalat Symposium. Excerpta Medica, Amsterdam Oxford Princeton, pp 209–217

    Google Scholar 

  17. Horowitz JD, Autman EM, Lorell BH, Barry WH, Smith TW (1983) Potentiation of cardio-vascular effects of nitroglycerin by N-acetylcysteine. Circulation 68: 1237–1253

    Article  Google Scholar 

  18. Ignarro U, Gruetter CA (1980) Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrate: Possible involvements of S-nitrothiols. Biochim Biophys Acta 631: 221–229

    PubMed  CAS  Google Scholar 

  19. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, Gruetter CA (1981) Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprus-side and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 218: 739–745

    PubMed  CAS  Google Scholar 

  20. Jansen W, Meyer L, Osterspray A, Eggling T, Tauchert M, Hilger HH (1986) Molsidomin unter Ruhe- und Belastungsbedingungen bei koronarer Herzkrankheit. Med Klinik 81: 489–495

    CAS  Google Scholar 

  21. Johnston GL, Gebhardt VA, Donald A, Kostiek WJ (1983) Comparative effects of propranolol and verpamil alone and in combination on left ventricular function and volumes in patients with chronic exertional angina: A double-blind, placebo-controlled, randomized crossover study with radionucleide ventriculography. Circulation 68: 1280–1288

    Article  PubMed  CAS  Google Scholar 

  22. Kenedi P, Giebler B (1983) Antianginal efficacy of long term nitrate therapy. Z Kardiol [Suppl 3] 72: 233–238

    Google Scholar 

  23. Lichtlen PR (1986) Angina on effort. In: Krebs R (ed) Treatment of cardiovascular disease by adalat (nifedipine). Schattauer, Stuttgart New York, pp 144–172

    Google Scholar 

  24. Lichtlen P, Halter J, Gattiker K (1974) The effect of isosorbide-dinitrate on coronary blood flow, coronary resistance and left ventricular dynamics in patients with coronary artery disease. Bas Res Card 49: 402–421

    Article  Google Scholar 

  25. Majid PA, de Jong JP (1983) Effects of nifedipine on left ventricular Performance in patients with ischemic heart disease. In: Kaltenbach M, Neufeld HN (eds) 5th International Adalat Symposium. Excerpta Medica, Amsterdam Oxford Princeton, pp 236–242

    Google Scholar 

  26. Mannes GA, Henge E, Jennerwein G, Rudolph W (1979) Doppelblind- und Einfachblind-studien zum Wirkungsnachweis von Molsidomin bei Patienten mit Angina pectoris. In: Lochner W, Bender F (Hrsg) Neue Aspekte in der Therapie der ischämischen Herzerkrankung. Urban & Schwarzenberg, München Wien Baltimore, S 200–206

    Google Scholar 

  27. Maseri A, Chierchia S, Kaski JC (1985) Mixed angina pectoris. Am J Cardiol 56: 30–33

    Article  Google Scholar 

  28. Miller AB, Conetta DA, Wainwright G, Mastria G, Wilhams D (1982) Nifedipine instable angina pectoris. A randomized double blind study. Chest 82: 241–247

    Google Scholar 

  29. Miller RR, Olsen HG, Amsterdam EA, Mason DT (1975) Propranolol withdrawal rebound phenomenon: Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med 293: 416–421

    Article  PubMed  CAS  Google Scholar 

  30. Ohlmeier H, Mertens H, Möller M, Mannebach H, Gleichmann U (1985) Akut- und Langzeitwirkung hochdosierter ISDN retard Einmal-Therapie. Z Kardiol [Suppl 3] 74: 82–86

    Google Scholar 

  31. Raue F, Ritz E, Akpan W, Enderle R, Neugebauer G (1985) Kinetics of IS-5-MN and its glucuronide in patients with renal failure. In: Cohn JN, Rittinghausen R (eds) Mononitrate. Springer, Berlin Heidelberg New York Tokyo, pp 78–85

    Google Scholar 

  32. Reichek W, Priest C, Zinirin D, Chandler T, Sutton MSJ (1984) Limited antianginal effects of nitroglycerin patches. Am J Cardiol 54: 1–7

    Article  PubMed  CAS  Google Scholar 

  33. Reimsch KD, Ziegler R (1986) Plasma concentrations of various nifedipine formulations in healthy volunteers. In: Lichtlen PR (ed) 6th International Adalat Symposium. Excerpta Medica, Amsterdam, pp 23–32

    Google Scholar 

  34. Reininger G, Blasini R, Brügmann U, Rudolph W (1984) Toleranzentwicklung hinsichtlich der antiischämischen Wirkung von Isosorbiddinitrat bei regelmäßiger, mehrfach täglicher Verabreichung. Herz 9: 146–152

    Google Scholar 

  35. Rennhak U, Riebesel T, Biamino G (1985) A double-blind cross over study on the effectiveness and possible development of tolerance during long term therapy with isosorbide-5-mononitrate or isorbide dinitrate slow-release in coronary artery disease. In: Cohn JN, Rittinghausen R (eds) Mononitrates. Springer, Berlin Heidelberg New York Tokyo, pp 147–153

    Google Scholar 

  36. Rudolph W, Fleck E, Dirschinger J (1982) Wirkung antianginöser Substanzen auf die Myokard- durchblutung. Herz 7: 378–387

    PubMed  CAS  Google Scholar 

  37. Schmidt DH, Weiss MB, Casarella WJ, Fowler DL, Sciacca RR, Cannon PJ (1976) Regional myocardial perfusion during atrial pacing in patients with coronary artery disease. Circulation 53: 807–819

    PubMed  CAS  Google Scholar 

  38. Schneider W, Stahl B, Bussmann WD, Kaltenbach M (1983) Long-term effects of high-dose ISDN therapy in patients with coronary heart disease. In: Kaltenbach M, Kober G (eds) Nitrates and nitrate tolerance in angina pectoris. Steinkopff, Darmstadt, S 131–137

    Google Scholar 

  39. Schultz W, Kober G, Krauss G, Kaltenbach M (1981) Influence of intracoronary and intra-venous nifedipine on diameters of coronary vessels and stenoses. In: Rafflenbeul W, Lichtlen PR, Balcon R (eds) Unstable angina pectoris. Thieme, Stuttgart, pp 259–265

    Google Scholar 

  40. Schultz W, Jost S, Kober G, Kaltenbach M (1985) Relation of antianginal efficacy of nifedipine to degree of coronary arterial narrowing and to presence of coronary collateral vessels. Am J Cardiol 55: 26–33

    Article  Google Scholar 

  41. Schulz S, Jost S, Kaltenbach M, Kober G (1983) Antianginöse Wirksamkeit des Kalzium-Antagonisten Nifedipin in Abhängigkeit vom Koronarbefall. Z Kardiol 72: 657–664

    PubMed  CAS  Google Scholar 

  42. Schuster P, Trieb G, Wiedemann HW (1983) Hemodynamic effect of isosorbide-5-mononitrate in acute and chronic treatment of coronary heart disease. Z Kardiol [Suppl 3] 72: 251–254

    Google Scholar 

  43. Silber S, Krause KH, Garner Ch, Theisen K, Jahrmärker H (1983) Anti-ischemic effects of an 80 mg tablet of isosorbide-dinitrate in sustained-release form before and after 2 weeks treatment with 80 mg once or twice daily. Z Kardiol [Suppl 3] 72: 211–218

    Google Scholar 

  44. Slany J, Mosslacher H, Schmoliner R, Kronik G (1976) Einfluß von Molsidomin auf Hämodynamik und Arbeitstoleranz bei Patienten mit Angina pectoris. Med Welt 49: 2396–2400

    Google Scholar 

  45. Thadani U, Sharma B, Meeran MK, Majid PA, Whitaker W, Taylor H (1973) Comparison of adrenergic betareceptor antagonists in angina pectoris. Br Med J 1: 138–146

    Article  PubMed  CAS  Google Scholar 

  46. Thadani U, Fung H, Darke AC, Parker JO (1980) Oral isosorbide dinitrate in the treatment of angina pectoris. Dose-response relationship and duration of action during acute therapy. Circulation 62: 491–502

    PubMed  CAS  Google Scholar 

  47. Vukovich RA, Foley JE, Brown B, et al (1979) Effect of betablockers on exercise double product (systolic blood pressure X heart rate). Br J Clin Pharmacol [Suppl 2] 7: 167–176

    Google Scholar 

  48. Winniford MD, Huxley RL, Hillis LD (1983) Randomized, double-blind comparison of propranolol alone and a propranolol-verapamile combination in patients with severe angina of effort. JACC 2: 492–498

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik I, Klinikum Großhadern der Ludwig-Maximilians-Universität, Marchioninistr. 15, D-8000, München 70, Germany

    G. Autenrieth

Authors
  1. G. Autenrieth
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinikum Großhadern, Ludwig-Maximilians-Universität, Marchioninistr. 15, D-8000, München 70, Germany

    Gerhard Riecker (Direktor der Medizinischen Klinik I) (Direktor der Medizinischen Klinik I)

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Autenrieth, G. (1988). Was ist gesichert in der medikamentösen Therapie der stabilen Angina pectoris?. In: Riecker, G. (eds) Koronare Herzkrankheit. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73255-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73255-3_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-18645-8

  • Online ISBN: 978-3-642-73255-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation